Lambda Light chain抗体;Lambda Light chain Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human plasma solution, Primary antibody: P11264(Lambda Light chain Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P11264(Lambda Light chain Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P11264(Lambda Light chain Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Lambda light chain antibodies are components of immunoglobulins, which are critical for adaptive immune responses. Antibodies consist of two heavy chains and two light chains, with light chains existing as either kappa (κ) or lambda (λ) types. The lambda light chain is encoded by the IGLC gene cluster on chromosome 22 and contributes to antigen-binding specificity through its variable region, while its constant region determines the light chain type.

Approximately 40% of human antibodies contain lambda light chains, with the κ:λ ratio in healthy individuals being roughly 2:1. This balance is tightly regulated, and deviations may indicate pathological conditions. For example, clonal proliferation of plasma cells in monoclonal gammopathies (e.g., multiple myeloma) often leads to overproduction of either free κ or λ light chains. Detection of abnormal lambda light chain levels in serum or urine serves as a diagnostic marker for such disorders.

Lambda light chain-specific antibodies are essential tools in research and diagnostics. They enable identification of light chain restriction in lymphoproliferative diseases through techniques like immunohistochemistry and flow cytometry. In clinical practice, immunoassays measuring serum free light chains (SFLC), including lambda chains, aid in monitoring disease progression and treatment response. Additionally, abnormal lambda light chain deposition is associated with conditions like light chain amyloidosis, where antibody-based detection supports early diagnosis. Understanding lambda light chain biology remains crucial for developing targeted therapies and improving diagnostic precision in hematological malignancies and related disorders.